Public BoD papers 28.04.22

Type of Research

Pre- Covid

Covid

Post- Covid

CTIMP) Other e.g observational, questionnaire

1855 2661

4107 4588

1449 2128

TOTAL number of patients

Table 5: NIHR Reported Performance in initiating clinical research and delivery Q2 21/22

Q3 21/22 21.5 days

Median days from date site confirmed (DSC) to date Site Selected (DSS) Median days from DSC to First Patient Recruited (FPR)

22 days

35.5 days

43 days

Median days DSS to FPR

73 days

81 days

Study Initiation

8 th position (of 185 trusts)

9 th position (of 189 trusts)

Recruiting to time and target

51.1%

51.1% (6 th position)

4. Ensure that R and I complies with all regulatory requirements governing research, provides assurance to funders and acts upon risks, audits and inspections CRF Strategic review action plan (November 2020) Action plan following review in November 2020 is monitored via management board Christie Charity Research A new assurance process for research and innovation related charitable fund investments has been established, reporting through to R and I Divisional Board.

Funding Assurance Including Academic Investment Plan NHSE Investigation ‘Christie Rapid Review’

A Task and Finish Group will be established within R and I to systematically address the recommendations to inform R and I Strategy Recommendations of the MHRA Inspection 2015 are not fully met and identified as high priority to address R and I Divisions will be subject to CQC Inspection. The Quality team is working on actions required to meet CQC Inspection criteria. • A SWOT analysis / review of current process is underway to inform quality improvement required for improved capacity and capability. • An action plan to ensure business continuity following the closure of the Manchester CTU is in place Actions to develop capacity and capability have commenced in collaboration with the new Director of Pharmacy, Damian Child Review of the current biobank model is underway due to reduced infrastructure funding 2022-2027 from CRUK Collaboration agreement is in discussion; Plans for occupation of the building by Christie staff have been presented at the Paterson Redevelopment Project Synergy and Steering Board Meetings.

MHRA Inspection Readiness CQC Inspection Readiness Christie Sponsored Research

Pharmacy research delivery

Manchester Cancer Research Centre Biobank

MCRC and Paterson Redevelopment

65